[
  {
    "sentence": "CRc was attained in 87% (N = 27/31; 95% CI, 71%–96%) overall and was 67% (N = 4/6; 95% CI, 27%–94%) in DL1, 100% (N = 6/6; 95% CI, 59%–100%) in DL2, 85% (N = 11/13; 95% CI: 57%–97%) in DL3, and 100% (N = 6/6; 95% CI, 59%–100%) in DL4 (Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Of the patients who attained MRD-MFC–negative CRc, 90% (N = 9/10) achieved this within 5 cycles of therapy (Fig. 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "IDH1 clearance was observed in 64% (N = 9/14; 95% CI, 37%–85%) of patients receiving ≥5 cycles compared with 8% (N = 1/13; 95% CI, 1%–34%) in those receiving 1 to 4 cycles (P = 0.004; Fig. 1C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Median OS was 26 months (95% CI, 4.1–NR) for DL1, and NR for DL2–4 (Fig. 2A); 12-month OS was 50% (SE 20%), 67% (SE: 19%), 85% (SE: 10%), and not estimated for DL1–4, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Median OS was 42 (95% CI, NR) months in patients with MDS or MPN, NR in ND-AML [estimated 12- and 24-month OS: 79% (SE: 11%) and 67% (SE: 14%)], and 9 months (95% CI: 8–NR) in R/R-AML (Fig. 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Conversely, a landmark analysis including surviving patients at EOC4 with evaluable MRD-MFC (N = 16) demonstrated clearance of MRD-MFC between cycles 1 to 4 was associated with a significant improvement in OS compared with patients with detectable MRD-MFC during this period (NR vs. 8 months, P = 0.0095); 12- and 24-month OS in patients with negative MRD-MFC CRc (N = 9) was 100% (SE: NA; Fig. 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Emergent mutations detected on bulk NGS at relapse included transcription factor mutations in 50% (N = 4; ETV6, RUNX1, and CEBPA); and signaling mutations in 25% (N = 2; NRAS, NF1, and PTPN11) of patients (Fig. 3A).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Methyl., methylation; T.S., tumor suppressor.Among patients with relapsed disease, 100% (N = 4) of patients with undetectable IDH1 using ddPCR in remission experienced relapse without recurrent IDH1 mutations; conversely, all (N = 4) patients with persistently detectable IDH1 mutations in remission had detectable IDH1 mutations at relapse (Fig. 3A).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Emergent mutations detected on bulk NGS at relapse included transcription factor mutations in 50% (N = 4; ETV6, RUNX1, and CEBPA); and signaling mutations in 25% (N = 2; NRAS, NF1, and PTPN11) of patients (Fig. 3A).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Among patients with relapsed disease, 100% (N = 4) of patients with undetectable IDH1 using ddPCR in remission experienced relapse without recurrent IDH1 mutations; conversely, all (N = 4) patients with persistently detectable IDH1 mutations in remission had detectable IDH1 mutations at relapse (Fig. 3A).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Relapse was driven by selective outgrowth of clones containing TP53 without IDH1 (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In a patient with sAML (accession #16) treated with 3 cycles of IVO + VEN + AZA, an IDH1 + NPM1 + NRAS G12A-mutated clone was replaced with emergent clones containing IDH1 + NPM1 with an alternative NRAS isoform G13R, and a clone containing KRAS (Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In a patient with ND-AML (accession #20) attaining a CRc with IVO + VEN + AZA most IDH1-mutated cells displayed a maturing myeloid progenitor phenotype (Fig. 4A–F) and were eliminated after one cycle of treatment, with subsequent expansion of CD14+ monocytic and IDH1 wild-type cell populations (Fig. 4G).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, persistent mutations in TET2, ASXL1, and to a lesser extent SRSF2 were observed in multiple cell populations including CD14+ monocyte/dendritic, CD16+ monocytic, primitive/maturing myeloid progenitor, and erythroid progenitor cell populations (Fig. 4A–F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "After transitioning to IVO maintenance while in remission (EOC1-EOC23) following C2 due to persistent cytopenias, a subsequent decrease in CD14+ monocytic populations was observed between EOC1 (when receiving AZA + VEN + IVO) and EOC7 (when receiving IVO maintenance) sampling (Fig. 4G).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      }
    ]
  }
]